Allogeneic Hematopoietic Stem Cells Transplantation for Non-Hodgkin’s Lymphoma. the Swiss Experience 1985-2014

Background: Efficacy of autologous hematopoietic stem cell transplantation (HST) and historically high NRM reported make allogeneic HSCT in Non-Hodgkin’s lymphoma (NHL) still a third line treatment. However, despite of a quick development of highly efficient targeted therapeutic antibodies alloHSCT still represents the only potentially curable treatment for several type of NHL. Introduction of reduced intensity conditioning regimens, amelioration of supportive care and graft-versus –host (GvHD) treatment lead to a global decreased of NRM rates, making use of alloHSCT much more attractive in a setting of relapse/refractory NHL. We report here the 20 years of Swiss experience in allo-HSCT for NHL.